Caffeine activates cell survival pathways in yeast, potentially slowing aging through energy and stress responses.

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

The addition of anagliptin to insulin and metformin therapy may improve glycemic control in patients with type 2 diabetes while maintaining an acceptable safety profile.

Metformin use may enhance progression-free survival (PFS) in patients receiving first-line systemic therapy for patients with ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

Rapamycin may match the benefits of eating less. Scientists are now exploring its potential to support healthy aging. The ...

Scientists have discovered that caffeine doesn’t just perk up your brain—it energizes your cells in a way that could slow ...

Semaglutide is linked to a reduced risk for Alzheimer’s disease-related dementia in patients with diabetes vs other antidiabetic drugs, a new study suggests.

Objective To confirm that metformin prevents flares in patients with SLE with low disease activity, we performed a post hoc analysis combining our previous two randomised trials.Methods Post hoc ...

For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is associated ...

The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes ...

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...